An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.

Autor:	Abdelbaki MS; Washington University School of Medicine, Department of Pediatrics, St. Louis, MO, United States., DeWire Schottmiller MD; Medpace, Cincinnati, OH, United States., Cripe TP; Nationwide Children's Hospital, Columbus, OH, United States., Curry RC; CTI Clinical Trials and Consulting, Covington, KY, United States., Cruze CA; Bexion Pharmaceuticals, Cincinnati, OH, United States., Her L; DataRevive, Rockville, MD, United States., Demko S; DataRevive, Rockville, MD, United States., Casey D; DataRevive, Rockville, MD, United States., Setty B; Nationwide Children's Hospital, Columbus, OH, United States.
Jazyk:	angličtina
Zdroj:	Heliyon [Heliyon] 2022 Dec 19; Vol. 8 (12), pp. e12450. Date of Electronic Publication: 2022 Dec 19 (Print Publication: 2022).
DOI:	10.1016/j.heliyon.2022.e12450
Abstrakt:	Background: BXQ-350 is a novel anti-neoplastic agent composed of saposin C (SapC) and phospholipid dioleoylphosphatidyl-serine sodium (DOPS) that selectively binds tumor cell phosphatidylserine (PS), inducing apoptosis. BXQ-350 has demonstrated preclinical antitumor effects in high-grade gliomas (HGG) and clinical activity in adult patients with recurrent HGG. Methods: A phase 1 study was conducted in pediatric patients with relapsed/refractory solid tumors, including recurrent brain tumors. Primary objectives were to characterize safety and determine maximum tolerated dose (MTD) and preliminary antitumor activity. Sequential dose cohorts were assessed up to 3.2 mg/kg using an accelerated titration design. Each cycle was 28 days; dosing occurred on days 1-5, 8, 10, 12, 15, and 22 of cycle 1, and day 1 of subsequent cycles, until disease progression or toxicity. Results: Nine patients, median age 10 years (range: 4-23), were enrolled. Seven patients (78%) had central nervous system (CNS) and two (22%) had non-CNS tumors. Eight patients completed cycle 1. No dose limiting toxicity (DLT) or BXQ-350-related serious adverse events (SAEs) were observed. Six patients experienced at least one adverse event (AE) considered possibly BXQ-350-related, most were grade ≤2. One patient with diffuse intrinsic pontine glioma experienced stable disease for 5 cycles. The study was terminated after part 1 to focus development on the frontline setting. Conclusion: No DLTs or BXQ-350-related SAEs were reported, and the maximal planned dose of 3.2 mg/kg IV was tolerable. Limited safety and efficacy data support continued BXQ-350 development in pediatric HGG; however, early discontinuations for progression suggest novel therapies be assessed at earlier disease stages. Competing Interests: The authors declare the following conflict of interests: Dr. Richard Curry has financial stock in Bexion Pharmaceuticals that total <1% of the company. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu